$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
The uses and effects of Jisandai (Bingtongsha)
2026-02-01 22:25:32
Check Details
Medication precautions for patients with Jisandai (Bingtonsha)
2026-02-01 22:25:32
Check Details
Ibrutinib/Ibrutinib Dosing and Purchasing Guide
2026-02-01 22:25:32
Check Details
Ibrutinib/ibrutinib drug description: manufacturer, drug properties and usage details
2026-02-01 22:25:32
Check Details
How toxic is ibrutinib/ibrutinib and how to deal with it?
2026-02-01 22:25:32
Check Details
Obeticholic acid generic drug manufacturers and price information
2026-02-01 22:25:32
Check Details
How effective is obeticholic acid and what are its side effects?
2026-02-01 22:25:32
Check Details
Overview of Chinese instructions for lorlatinib/lorlatinib
2026-02-01 22:25:32
Check Details
What are the side effects or side effects of lorlatinib/lorlatinib?
2026-02-01 22:25:32
Check Details
Lorlatinib/lorlatinib belongs to which generation of targeted drugs
2026-02-01 22:25:32
Check Details
How many years should you take lorlatinib/lorlatinib for the longest time?
2026-02-01 22:25:32
Check Details
How much does it cost to buy a box of lorlatinib/lorlatinib tablets in 2024?
2026-02-01 22:25:32
Check Details
1
2
...
963
964
965
966
967
968
969
...
10223
10224
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tazemetostat Dosage Guide: Laos Generic vs. Original Tazverik Comparison
2
Tivozanib: A Next-Generation Highly Selective VEGFR-Targeted Therapy Explained
3
Capmatinib Clinical Guide: Drug Comparisons, Treatment Strategies, and Combination Therapy Prospects
4
Avatrombopag Complete Guide: Efficacy, Indications, and TPO-RA Drug Comparisons
5
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
6
Venetoclax Clinical Guide: Mechanism, Indications, and Originator vs. Generic Comparison
7
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
8
Elagolix Side Effects and Safety Guide
9
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
10
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
11
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
12
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA